Polyplus acquired e-Zyvec, which provides DNA design and production services for DNA vectors for gene therapy, biomanufacturing, and research.
“When we launched e-Zyvec five years ago, the idea was to bring a different type of genetic engineering service to the market leveraging today’s digital technology. Moving forward, we are excited to now join an established market leader like Polyplus where we will have the resources and capacity to continue developing and growing the e-Zyvec platform,” said Sylvain Julien, president and co-founder at e-Zyvec.
“Joining the Polyplus team is an organic transition for our team, enabling us to expand this technology across the global market,” added Carine Morel, managing director and co-founder at e-Zyvec.
“Polyplus is evolving and growing, and this latest acquisition is an example of our strategy in action,” said Mario Phillips, CEO of Polyplus, which manufactures transfection solutions. “We will continue to build out the existing portfolio, which is strong on its own, by adding complementary activities that make us a more effective and comprehensive partner to our customers, with a focus on expanding process economics optimization efforts for cell and gene therapy developers and manufacturers.”
